pre-IPO PHARMA

COMPANY OVERVIEW

FORMA Therapeutics’ scientists are passionate about discovering and developing medicines that will make a difference in oncology, inflammation & immunity, neurodegeneration, and other serious diseases. The Company’s fully integrated R&D team drives discovery and early clinical development of therapeutics for qualified targets in the areas of epigenetics, protein homeostasis, and metabolism. Leveraging a world class network of academic investigators, clinical experts and partners, FORMA combines deep biology insight, chemistry expertise and early clinical development capabilities, to create drug candidates providing profound patient benefit.


LOCATION

  • Watertown, MA, USA
  • Branford, CT, USA

  • THERAPEUTIC AREAS

  • Immunology
  • Inflammatory Disease
  • Neurodegenerative Disease
  • Oncology

  • WEBSITE

    https://www.formatherapeutics.com


    CAREER WEBSITE

    https://www.formatherapeutics.com/join-us/


    SOCIAL MEDIA


    INVESTORS

    edbi lilly-ventures novartis-venture-fund


    PRESS RELEASES


    Jun 18, 2020

    Forma Therapeutics Announces Pricing of Initial Public Offering


    Jun 12, 2020

    Forma Therapeutics Presents Safety, Pharmacokinetic and Pharmacodynamic Data from Phase 1 Clinical Trial for Investigational Agent FT-4202 in Patients with Sickle Cell Disease


    Jun 9, 2020

    Forma Therapeutics Announces Phase I Clinical Data for Investigational Agent FT-4202 in Sickle Cell Disease to be Presented at the Virtual Edition of the 25th European Hematology Association Annual Congress


    May 28, 2020

    Forma Therapeutics Announces Clinical Data to be Presented at ASCO20 Virtual Scientific Program


    Apr 28, 2020

    Forma Therapeutics Appoints David N. Cook, Ph.D., to Chief Scientific Officer


    For More Press Releases


    Google Analytics Alternative